Universal Health Services enters its third-quarter report with an awkward mismatch. Last quarter, management trimmed its full-year outlook and layered in a string of new headwinds. Since then, the stock has climbed nearly 24%, beating the S&P 500 by more than 20 percentage points. Investors have essentially bet that the guidance cut cleared the decks. The October 27 release, due after the close, is the first real chance to see whether that bet was right.

The Street expects earnings of $5.33 per share on revenue of about $4.73 billion. That implies a 6.3% decline in EPS from the $5.69 earned a year ago, even as revenue grows a respectable 5.2%. Part of the year-over-year squeeze reflects tougher cost items management flagged, and the sequential drop from the second quarter's $5.98 is less alarming than it looks. That figure was flattered by a roughly $100 million out-of-period Florida supplemental payment, which won't recur. The whisper number of $5.55 sits about 4% above consensus, so the informal bar is meaningfully higher than the published one. For the full year, management now guides to $22.28 to $23.65 per share, down from $22.64 to $24.52. Consensus of $23.44 sits in the upper part of that range, which suggests analysts expect the company to land well above the midpoint despite the cut.

The second-quarter call offered two competing stories. The encouraging one was acute care demand. Same-facility adjusted admissions rose 2.9% after flat readings in the two prior quarters, and the improvement was geographically broad. Surgical volumes also improved to a decline of less than 1%. Yet management lowered its acute volume range to 1.5% to 2.5%, so a third quarter that holds near the second quarter's pace would validate the rebound. A slide back toward flat would suggest the spring was a blip. Investors should also look for early contribution from the 177 new acute beds and the Palm Beach Gardens hospital, which together represent the company's organic growth runway.

The less encouraging story was the core business excluding supplemental payments, which fell roughly $63 million short of internal plans in the second quarter. Behavioral health is the bigger worry. Its volume guide was cut a full percentage point to 1% to 2%, and the San Antonio facility's loss of certification removes about $50 million of earnings this year, with recertification not expected until 2027. Signs that behavioral volumes are stabilizing would carry real weight. So would evidence that the Cedar Hill de novo in Washington is tracking toward its delayed fourth-quarter breakeven. On the cost side, malpractice reserves were raised about $50 million because of rising claims severity across the industry. Any further increase would signal that the problem is still getting worse. The company also raised its estimate of the hit from lapsing exchange enrollees to about $85 million. Those patients are moving almost one for one into self-pay, so uncompensated care trends deserve attention too.

Sentiment has swung from 15.4% bearish before last quarter's report to slightly bullish now. The shift is modest, but it fits a stock that has rebuilt confidence. Shares trade at $185.10, above the 200-day moving average and within about 3% of the post-earnings high of $190.55, so the stock is testing a breakout. Aggressive buybacks, including $320 million last quarter and nearly $1 billion of remaining authorization, have helped support per-share results and the rally.

The central question is whether the core business can carry its own weight now that one-time supplemental help has faded. If acute volumes hold, behavioral trends stabilize and no new reserve charges appear, the lowered guidance will look conservative and the rally will look earned. Another round of operational shortfalls would suggest the stock got ahead of the fundamentals.